Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication

Inclusion Criteria: * Consenting to an endoscopy * Signing the informed consent form * Not receiving Helicobacter pylori eradication treatment before * Showing Helicobacter pylori infection by rapid urease test and/or Giemsa staining * Being older than 18 years of age Exclusion Criteria: * Being younger than 18 years of age * Receiving H. pylori eradication treatment previously * Having gastrectomy or vagotomy in medical history * Having gastric malignancy, including adenocarcinoma and lymphoma * Having other severe malignant disease * Previously having allergic reaction to antibiotics (amoxicillin, levofloxacin) and proton pump inhibitors (lansoprazole) * Using prompt pump inhibitors (lansoprazole) and antibiotics (amoxicillin, clarithromycin, levofloxacin) in the last 4 weeks * Having active upper GI bleeding in the last week * Being pregnant or lactating * Taking long term high dosages of aspirin, corticosteroid and other NSAIDs in the last 4 weeks * Taking any antibiotics or proton pump inhibitors other than the study medication during the study period * Taking antacids and/or H2-blockers during the study period * Taking bismuth compounds within four weeks prior to and during the study period * Having dysphasia or vomiting as major symptoms * Having psychiatric, neurological, or behavioral disorders that may interfere with the conduct or interpretation of the study * Having severe concomitant disease of the cardiovascular, pulmonic, hepatic, renal, hematological, lymphatic, metabolic, and endocrine system. * Having known uncontrolled hypertension * Being immunocompromised * Showing clinically significant abnormal vital signs * Having clinically significant abnormal ECG findings * Presenting clinically significant abnormal laboratory data at screening, or any abnormal laboratory value that could interfere with the assessment of safety * Being exposed to any investigational drug within 30 days prior to screening * Having known hypersensitivity to or contraindication against fluoroquinolones. * Having current diagnosis or known history of substance abuse.